We are live on ! Find out more
Federated Hermes

Federated Hermes Portfolio holdings

AUM $69.6B
1-Year Est. Return 42.52%
This Fund
S&P 500
This Quarter Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
Cap. Flow
-$952M
Cap. Flow %
-2.26%
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$156M
2
PLD icon
Prologis
PLD
+$150M
3
CVX icon
Chevron
CVX
+$109M
4
QCOM icon
Qualcomm
QCOM
+$101M
5
PAYC icon
Paycom
PAYC
+$90.8M

Sector Composition

Rank Sector Weight
1 Technology 18.81%
2 Healthcare 17.11%
3 Financials 12.73%
4 Industrials 9.87%
5 Consumer Discretionary 9.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FTNT icon
326
Fortinet
FTNT
$126B
$27.3M 0.06%
452,947
+377,035
+497% +$23.4M
WST icon
327
West Pharmaceutical
WST
$25.7B
$27.1M 0.06%
82,403
-19,122
-19% -$6.76M
BRBR icon
328
BellRing Brands
BRBR
$1.06B
$27.1M 0.06%
474,168
+103,604
+28% +$5.93M
KNF icon
329
Knife River
KNF
$3.21B
$26.9M 0.06%
384,215
+104,720
+37% +$7.82M
OMCL icon
330
Omnicell
OMCL
$1.49B
$26.8M 0.06%
991,151
+909,480
+1,114% +$26.3M
ATKR icon
331
Atkore
ATKR
$3.19B
$26.8M 0.06%
198,273
-129,089
-39% -$20.6M
IT icon
332
Gartner
IT
$12.4B
$26.7M 0.06%
59,393
+4,887
+9% +$2.17M
ELV icon
333
Elevance Health
ELV
$90.6B
$26.6M 0.06%
49,167
+861
+2% +$455K
CHX
334
DELISTED
ChampionX
CHX
$26.5M 0.06%
798,279
+72,549
+10% +$2.47M
ALL icon
335
Allstate
ALL
$65B
$26.4M 0.06%
165,303
-10,168
-6% -$1.7M
MRO
336
DELISTED
Marathon Oil Corporation
MRO
$26.4M 0.06%
920,469
+8,050
+0.9% +$223K
CGNX icon
337
Cognex
CGNX
$9.95B
$26.3M 0.06%
563,252
+39,328
+8% +$1.73M
AOS icon
338
A.O. Smith
AOS
$7.78B
$26.2M 0.06%
320,562
-50,189
-14% -$4.25M
HCP
339
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
$26.1M 0.06%
775,800
-1,718,792
-69% -$53.4M
CAH icon
340
Cardinal Health
CAH
$54.1B
$25.9M 0.06%
263,307
-43,746
-14% -$4.46M
COLD icon
341
Americold
COLD
$4.28B
$25.9M 0.06%
1,012,456
-892,703
-47% -$21.9M
BIO icon
342
Bio-Rad Laboratories Class A
BIO
$10.1B
$25.8M 0.06%
94,436
+4,253
+5% +$1.24M
POWI icon
343
Power Integrations
POWI
$2.7B
$25.7M 0.06%
366,365
+22,030
+6% +$1.58M
ICUI icon
344
ICU Medical
ICUI
$3.9B
$25.6M 0.06%
215,808
+18,301
+9% +$1.93M
STNE icon
345
StoneCo
STNE
$2.23B
$25.5M 0.06%
2,129,571
-835,293
-28% -$12.3M
HCA icon
346
HCA Healthcare
HCA
$91.8B
$25.5M 0.06%
79,277
-1,911
-2% -$621K
STM icon
347
STMicroelectronics
STM
$42.7B
$25.5M 0.06%
648,403
+364,184
+128% +$15.1M
GO icon
348
Grocery Outlet
GO
$1.14B
$25.4M 0.06%
1,150,136
-261,486
-19% -$6.2M
UNP icon
349
Union Pacific
UNP
$169B
$25.4M 0.06%
112,292
+109,194
+3,525% +$25.6M
TXRH icon
350
Texas Roadhouse
TXRH
$11.1B
$25.3M 0.06%
147,553
+9,618
+7% +$1.57M

Similar funds

Federated Hermes's Q2 2024 Portfolio in Review

As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.

  • Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
  • Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
  • Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
  • Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
  • Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
  • Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
  • Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.